Topical drug delivery in the oral mucosa has its set of challenges due to the unique anatomical and physiological features of the oral cavity. As such, the outcomes of local pharmacological treatments in oral disorders can fail due to unsuccessfully drug delivery. Oral mucositis, a severe inflammatory and ulcerative side effect of oncological treatments, is one of such diseases. Although the damaged tissue is within reach, no approved topical drug treatment is available. Several strategies based on its physiopathology have been implemented and clinically used. Even so, results tend to lack or be insufficient to improve patient's quality of life. The use of corticosteroids has been employed in such strategies due to their strong anti-inflammatory action. Typically, these are administrated in simple liquid formulations, where the drug is dispersed or solubilized, lacking the ability to maintain local concentration. In this work, we propose the development of a biocompatible delivery system with boosted abilities of retention and control release of budesonide, a corticosteroid with an elevated ratio of topical anti-inflammatory to systemic action. Through spray-drying, polymeric particles of Chitosan and Eudragit® E PO were produced and characterized for the vectorization of this drug.
Keywords: Budesonide; Budesonide (CAS number: 51333-22-3); Chitosan; Chitosan (CAS number: 9012-76-4); Drug-delivery; Eudragit® E PO; Eudragit® E PO (CAS number: 24938-16-7); Glacial Acetic Acid (CAS number: 64-19-7); Oral mucositis; Spray-drying; Tween® 20 (CAS number: 9005-64-5)..
Copyright © 2019 Elsevier B.V. All rights reserved.